Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477235 | 0.89 | PIK3CA (0.75) | PIK3CAPIK3CBPIK3R1PIK3CDPIK3CG | |
| SCHEMBL2813677 | 0.88 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3R1PIK3CD | |
| SCHEMBL477863 | 0.84 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3R1PIK3CD | |
| SCHEMBL6518517 | 0.84 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3R1PIK3CDPIK3CG | |
| SCHEMBL477302 | 0.84 | PIK3CA (0.61) | PIK3CAPIK3CBPIK3R1PIK3CDPIK3CG | |
| SCHEMBL2811667 | 0.84 | PIK3CA (0.73) | PIK3CAPIK3CBPIK3R1PIK3CD | |
| SCHEMBL2813608 | 0.83 | PIK3CA (0.65) | PIK3CAPIK3CBPIK3R1PIK3CD | |
| SCHEMBL4526879 | 0.82 | PIK3CB (0.76) | PIK3CAPIK3CBPIK3R1PIK3CDPIK3CG | |
| SCHEMBL2817610 | 0.81 | PIK3CA (0.72) | PIK3CAPIK3CBPIK3R1PIK3CD | |
| SCHEMBL6517150 | 0.81 | PIK3CB (0.76) | PIK3CAPIK3CBPIK3R1PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411387-B1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | VETDC INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2013-10-31 | — | — | US | disclosed |
| US-8461158-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | PIK3CA 99/4885PIK3CB 172/4885PIK3R1 1213/4885 |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | PIK3CA 99/4885PIK3CB 172/4885PIK3R1 1213/4885 |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | PIK3CA 99/4885PIK3CB 172/4885PIK3R1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.